TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8830977

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan hydrobromide
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenotyping using metabolic ratios
Number of subjects: 7
Study: 1309476

Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Wheat fiber
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Wheat germ
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rice bran
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (low-fiber test meal)
Number of subjects: 6
Study: 6729671

Group type: EXPERIMENTAL
Intervention: Herniography pre- and postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Herniectomy without ligation of the sac
Number of subjects: 0
Study: 30813694

Group type: EXPERIMENTAL
Intervention: Butylphthalide treatment group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-invasive ventilation control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Butylphthalide combined with non-invasive ventilation group
Number of subjects: 120
Study: 29474441

Group type: EXPERIMENTAL
Intervention: Expressive Writing Intervention (EWI)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Expressive Writing Intervention (EWI) - writing about their own cancer
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control - non-disclosing topic
Number of subjects: 507
Study: 26577208

Group type: EXPERIMENTAL
Intervention: Physiological exertion above the second lactate threshold (LT2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Light and moderate-intensity exercise below the LT2
Number of subjects: 28
Study: 22514730

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP) administered early (4 months of gestation)
Number of subjects: 1439

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP) administered late (6-7 months of gestation)
Number of subjects: 1439
Study: 20573791

Group type: EXPERIMENTAL
Intervention: (6S)-[(13)C(5)]5-CH(3)-H(4) folate from whole-meal bread
Number of subjects: 8

Group type: COMPARATOR
Intervention: [(13)C(5)]folic acid from fortified bread
Number of subjects: 8

Group type: COMPARATOR
Intervention: [(13)C(5)]folic acid from fortified breakfast meal
Number of subjects: 8
Study: 18405788

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alogliptin 400 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15888152

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg kg(‐1)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg(‐1)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 12766522

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (e.g., amiodarone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients experiencing shocks from ICDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple shocks from ICDs
Number of subjects: 0
Study: 10667832

Group type: EXPERIMENTAL
Intervention: Dexibuprofen 400 mg t.i.d.
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Dexibuprofen 200 mg t.i.d.
Number of subjects: 178

Group type: COMPARATOR
Intervention: Racemic ibuprofen 800 mg t.i.d.
Number of subjects: 178
Study: 9006224

Group type: EXPERIMENTAL
Intervention: Patient-centred consulting training programme
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Observation of diabetes review consultations before and after training
Number of subjects: 55
Study: 1297554

Group type: EXPERIMENTAL
Intervention: Cervical collar therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Natural course (control)
Number of subjects: 32
Study: 3906995

Group type: EXPERIMENTAL
Intervention: Chlorbutin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: D-penicillamine (large and mean doses)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NAID)
Number of subjects: 186
Study: 30578651

Group type: EXPERIMENTAL
Intervention: normoxic helium‐oxygen (HEL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: inspiratory resistance (RES) of ∼5 cmH2O L−1 s−1
Number of subjects: 18

Group type: COMPARATOR
Intervention: ambient air (CON)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall dyspnoea intensity
Number of subjects: 18
Study: 29622281

Group type: EXPERIMENTAL
Intervention: Education group (self-management education)
Number of subjects: 118
Study: 26851152

Group type: EXPERIMENTAL
Intervention: Healthy Habits, Healthy Girls-Brazil program
Number of subjects: 253
Study: 24812899

Group type: EXPERIMENTAL
Intervention: Ningdong Granule (NG), one dose daily for 3 months, dissolved in boiled water, taken in two portions in the morning and evening.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment with NG and Tiapride, equal doses for 3 months.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tiapride Tablet, 50-100 mg twice daily for 3 months, max dosage 300 mg per day.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy control group, no intervention.
Number of subjects: 90
Study: 23044291

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 122
Study: 19680706

Group type: EXPERIMENTAL
Intervention: Real rTMS (left prefrontal 10 Hz)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study: 17932094

Group type: EXPERIMENTAL
Intervention: Complete ST resolution (> or =50%)
Number of subjects: 4565

Group type: EXPERIMENTAL
Intervention: Anterior myocardial infarction (MI) in the highest quartile of SigmaSTD with complete ST resolution
Number of subjects: 4565

Group type: EXPERIMENTAL
Intervention: Anterior myocardial infarction (MI) in the highest quartile of SigmaSTD with incomplete ST resolution
Number of subjects: 4565

Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction (MI) with incomplete ST resolution
Number of subjects: 4565
Study: 18204271

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LPI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Regular insulin (RGI)
Number of subjects: 103
Study: 15125006

Group type: EXPERIMENTAL
Intervention: Peripheral bone densitometry (PD) system (GE/Lunar PIXI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Computed radiography (CR) system (Fuji)
Number of subjects: 24
Study: 11379380

Group type: EXPERIMENTAL
Intervention: Continuous estradiol 50 micrograms/24 h with vaginal progesterone gel 8 mg every 2nd day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous estradiol 50 micrograms/24 h with medroxyprogesterone acetate 5 mg/day orally during 12 days per month
Number of subjects: 12
Study: 9404445

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (250 mg testosterone enanthate/month for four months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (age-matched pubertal controls)
Number of subjects: 19
Study: 8321561

Group type: EXPERIMENTAL
Intervention: Constavac autoreinfusion device
Number of subjects: 91

Group type: COMPARATOR
Intervention: Hemovac standard suction device
Number of subjects: 91
Study: 3463572

Group type: EXPERIMENTAL
Intervention: 0.1% folate mouthwash
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 20
Study: 11451839

Group type: EXPERIMENTAL
Intervention: recombinant human deoxyribonuclease I (rhDNase)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 31147085

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 654

Group type: COMPARATOR
Intervention: Standard postpartum care (Control)
Number of subjects: 654
Study: 30007535

Group type: EXPERIMENTAL
Intervention: PACE (Patient Centered Weight Loss Program) starting ≤6 weeks before surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed PACE (Patient Centered Weight Loss Program) starting at 12 weeks post-op
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (PACE and Delayed PACE)
Number of subjects: 16
Study: 27659544

Group type: EXPERIMENTAL
Intervention: UT‐DSAEK
Number of subjects: 66

Group type: COMPARATOR
Intervention: DSAEK
Number of subjects: 66
Study: 25049329

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - docetaxel 75 mg/m² on day 1, cisplatin 75 mg/m² on day 1, fluorouracil 750 mg/m² on days 1 to 5, followed by CRT (docetaxel, fluorouracil, hydroxyurea plus radiotherapy 0.15 Gy twice per day every other week)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone - docetaxel, fluorouracil, and hydroxyurea plus radiotherapy 0.15 Gy twice per day every other week
Number of subjects: 285
Study: 22215218

Group type: EXPERIMENTAL
Intervention: Ultra early cranioplasty (reimplantation of the patient's own skull flap)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Early cranioplasty (7-12 weeks)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Delayed cranioplasty (after 13 weeks)
Number of subjects: 242
Study: 20083373

Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen) 4 g daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 19226897

Group type: EXPERIMENTAL
Intervention: Visceral differentiation-based acupuncture therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine acupuncture therapy
Number of subjects: 70
Study: 16028648

Group type: EXPERIMENTAL
Intervention: Sustained pressure-controlled inflation (15 s)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (rate 60 min(‐1))
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 61
Study: 11987872

Group type: EXPERIMENTAL
Intervention: Original training stimulus exposure
Number of subjects: 85

Group type: COMPARATOR
Intervention: Different mobile or context exposure
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Testing after increasing delays with original stimulus, exposed stimulus, or novel stimulus
Number of subjects: 85
Study: 10577566

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 362

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 362
Study: 7489976

Group type: EXPERIMENTAL
Intervention: Fish oil (12 g daily for 2 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Corn oil (12 g daily for 2 months)
Number of subjects: 26
Study: 2278890

Group type: EXPERIMENTAL
Intervention: Routine radionuclide bone scans every 6 months during the first 2 years of follow-up
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Routine radionuclide bone scans
Number of subjects: 560
Study: 87094

Group type: EXPERIMENTAL
Intervention: Tenutex (0.5% DDT, 2% disulfiram, 22.5% benzyl benzoate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: DDT-free Tenutex emulsion (2% disulfiram, 22.5% benzyl benzoate)
Number of subjects: 38
Study: 30904595

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg PRN
Number of subjects: 0
Study: 30022334

Group type: EXPERIMENTAL
Intervention: Structured written and verbal education by community pharmacists
Number of subjects: 64

Group type: COMPARATOR
Intervention: Verbal advice only (Control)
Number of subjects: 64
Study: 26174879

Group type: EXPERIMENTAL
Intervention: Adapted Sangha comorbidity index
Number of subjects: 7808

Group type: EXPERIMENTAL
Intervention: Adapted Wolfe comorbidity index
Number of subjects: 7808
Study: 25127405

Group type: EXPERIMENTAL
Intervention: NRT (15 mg/16 h transdermal patches)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study: 22748590

Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 708

Group type: COMPARATOR
Intervention: ATV/RTV+FTC/TDF
Number of subjects: 708
Study: 19890256

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18041489

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Automated scoring by Morpheus with full manual review
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Automated scoring by Morpheus with partial manual review
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Automated scoring by Somnolyzer24X7 with partial manual review
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Full manual scoring
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Automated scoring by Morpheus
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Automated scoring by Somnolyzer24X7
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 16050054

Group type: EXPERIMENTAL
Intervention: Omega-3 FA + policosanol 5 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omega-3 FA + policosanol 10 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Omega-3 FA + placebo
Number of subjects: 90
Study: 14624217

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other coagulation modulators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard management protocols
Number of subjects: 0
Study: 11221091

Group type: EXPERIMENTAL
Intervention: ROM plus low-dose Convit vaccine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single-dose ROM therapy
Number of subjects: 90
Study: 8971431

Group type: EXPERIMENTAL
Intervention: 10 mg controlled-release (CR) oxycodone tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20 mg immediate-release (IR) oxycodone oral solution
Number of subjects: 24
Study: 1732652

Group type: EXPERIMENTAL
Intervention: 720 mL/d of caffeinated coffee
Number of subjects: 100
Study: 6147256

Group type: EXPERIMENTAL
Intervention: Chloranolol (Tobanum)
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Uncontrolled questionnaire inquiry (no placebo)
Number of subjects: 2066
Study: 29571681

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 26
Study: 30545427

Group type: EXPERIMENTAL
Intervention: Theory-based messaging intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27107906

Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block (CG)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Single-shot group (SSG)
Number of subjects: 85
Study: 23823716

Group type: EXPERIMENTAL
Intervention: Cocoa product rich in fibre (15 g each, 2 servings daily for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Milk (control)
Number of subjects: 44
Study: 22167566

Group type: EXPERIMENTAL
Intervention: High-fat meal with 25 mg preladenant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting with 25 mg preladenant
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-fat meal with SCH434748
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting with SCH434748
Number of subjects: 24
Study: 20018913

Group type: EXPERIMENTAL
Intervention: Maintenance treatment using intermittent ATRA
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Maintenance treatment using continuous 6 mercaptopurine plus methotrexate
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Both maintenance treatments
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Early addition of CT to ATRA
Number of subjects: 576

Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Age-related cumulative incidence of deaths in complete response (CR)
Number of subjects: 576
Study: 18627001

Group type: EXPERIMENTAL
Intervention: Nighttime nutritional supplementation (710 kcal/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Daytime nutritional supplementation (710 kcal/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Both groups (daytime and nighttime)
Number of subjects: 103
Study: 15801944

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg in males with renal impairment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Raloxifene 120 mg in healthy males
Number of subjects: 20
Study: 12162932

Group type: EXPERIMENTAL
Intervention: Statin therapy (lovastatin, pravastatin, simvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lovastatin, pravastatin, simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other statins (in long-term trials)
Number of subjects: 0
Study: 9602956

Group type: EXPERIMENTAL
Intervention: 300-mg irbesartan tablet under fasted conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: 300-mg irbesartan tablet 5 minutes after a high-fat breakfast
Number of subjects: 16
Study: 8043714

Group type: EXPERIMENTAL
Intervention: DP-Gln 20 (gly-gln, gly-tyr)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vamin 18EF
Number of subjects: 16
Study: 2742010

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31603867

Group type: EXPERIMENTAL
Intervention: Follicular phase acupuncture for 30-40 minutes
Number of subjects: 102

Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 102
Study: 29542371

Group type: EXPERIMENTAL
Intervention: 100 mg ketamine
Number of subjects: 5

Group type: COMPARATOR
Intervention: 4.5 mg midazolam
Number of subjects: 5
Study: 26902307

Group type: EXPERIMENTAL
Intervention: 400 mg single-dose albendazole administration
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 60000 μg vitamin A capsule combined with 400 mg single-dose albendazole
Number of subjects: 209

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 209
Study: 25288348

Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid injection (40 mg triamcinolone acetonide)
Number of subjects: 62
Study: 22316635

Group type: EXPERIMENTAL
Intervention: Pardoprunox (up to 42 mg/day)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Pardoprunox
Number of subjects: 294
Study: 20110117

Group type: EXPERIMENTAL
Intervention: 10 IU/kg of botulinum toxin A injected into the detrusor muscle (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 IU/kg of botulinum toxin A injected into the detrusor muscle and 2 IU/kg through 4 injections in external urethral sphincter (Group B)
Number of subjects: 60
Study: 17922221

Group type: EXPERIMENTAL
Intervention: Embedded FACT Head and Neck Symptom Index (FHNSI)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Stand-alone FACT Head and Neck Symptom Index (FHNSI)
Number of subjects: 98
Study: 17966578

Group type: EXPERIMENTAL
Intervention: Strains 638 and 1333
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strains 81, 638, 638T and 1333
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All strains
Number of subjects: 0
Study: 14983322

Group type: EXPERIMENTAL
Intervention: tinidazole‐iodoform‐phenocamphor paste
Number of subjects: 80

Group type: COMPARATOR
Intervention: formocresol
Number of subjects: 80
Study: 9862558

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Phenelzine therapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Pill placebo administration
Number of subjects: 133

Group type: COMPARATOR
Intervention: Educational-supportive group therapy
Number of subjects: 133
Study: 7695309

Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg single dose
Number of subjects: 463

Group type: COMPARATOR
Intervention: Pefloxacin 800 mg single dose
Number of subjects: 463
Study: 2781664

Group type: EXPERIMENTAL
Intervention: Removal of dressings on the first postoperative day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Removal of dressings on the fifth postoperative day
Number of subjects: 200
Study: 827989

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic administration
Number of subjects: 400

Group type: COMPARATOR
Intervention: Postoperative antibiotic administration
Number of subjects: 400
Study: 7326269

Group type: EXPERIMENTAL
Intervention: 40 minutes of feedback in pulse rate (PR) change
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback in pulse rate (PR) change
Number of subjects: 0
Study: 31611038

Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg once daily for 12 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo once daily for 12 months
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg once daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study: 29053120

Group type: EXPERIMENTAL
Intervention: Divaza (2 tablets 3 times a day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 26323041

Group type: EXPERIMENTAL
Intervention: Dopamine (5-10 μg/kg/min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epinephrine (0.1-0.3 μg/kg/min)
Number of subjects: 120
Study: 24292818

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (IFF; 0.8-1.0 mg iron/100 ml)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 138
Study: 21944649

Group type: EXPERIMENTAL
Intervention: Postauricular approach
Number of subjects: 15

Group type: COMPARATOR
Intervention: Preauricular approach
Number of subjects: 15
Study: 19756530

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17562959

Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: CPAP-CSA suppressed (n=57)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: CPAP-CSA unsuppressed (n=43)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (n=130)
Number of subjects: 258